Dr. Reddy’s Launches Generic Oral Anti-Epileptic Drug In U.S.
A group of pink tablets for medical treatment are arranged for a photograph at a pharmacy in Indonesia. (Photographer: Dimas Ardian/Bloomberg)  

Dr. Reddy’s Launches Generic Oral Anti-Epileptic Drug In U.S.


Dr. Reddy's Laboratories Ltd. said it has launched generic anti-epileptic Vigabatrin powder for oral solution in the U.S. market.

The product is a generic version of Lundbeck’s Sabril powder for oral solution, Dr. Reddy’s said in a filing to the BSE.

The company has launched Vigabatrin powder for oral solution, USP in 500 milligram per packet after getting approval by the U.S. Food and Drug Administration, it said.

According to IMS Health data, Sabril brand and generic had U.S. sales of around $274 million (about Rs 1,900 crore) MAT for the most recent twelve months ending in June 2019, Dr. Reddy’s said.

Sabril is indicated as adjunctive therapy for adults and pediatric patients of 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.

Shares of Dr. Reddy’s Laboratories closed at Rs 2,554.90 per scrip on the BSE, up 1.77 per cent from its previous close.

Also read: AstraZeneca Moves U.S. Court Against Dr Reddy’s On Brilinta Generic Drug

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.